Maze Therapeutics, Inc. Form 4 Filings

Maze Therapeutics, Inc. (MAZE) reported that its General Counsel and Corporate Secretary, Courtney Phillips, sold a total of 3,993 shares of common stock on September 2–3, 2026. The company states these sales were made to satisfy tax withholding obligations arising from the vesting of restricted stock units, and no Rule 10b5-1 trading plan is reported.

Maze Therapeutics, Inc. (MAZE) reports that officer Atul Dandekar, its CSBO, sold 6,434 shares of Common Stock on September 2 and 3, 2026. The company states these sales were made to satisfy tax withholding obligations arising from the vesting of restricted stock units and not as discretionary open-market sales. The shares were sold in multiple transactions at weighted average prices within ranges from $25.743 to $27.40 per share, and no Rule 10b5-1 trading plan is reported.

Maze Therapeutics, Inc. (MAZE) reported that Chief Executive Officer and director Jason V. Coloma sold an aggregate of 22,638 shares of Common Stock on September 2–3, 2026, in open-market or private transactions to satisfy tax withholding obligations incurred upon the vesting of restricted stock units.

The reported weighted average prices were $26.3760 and $27.1211 per share on September 2, 2026, and $26.0133 and $25.7749 per share on September 3, 2026, with individual trades executed within the price ranges described in the footnotes. Coloma is also reported as having indirect ownership of 18,151 shares held by The Coloma 2021 Irrevocable Trust and 223,355 shares held by the Coloma Family Trust, for which he and his spouse serve as co‑trustees.

Maze Therapeutics, Inc. (MAZE) reported that Harold Bernstein, President, R&D & CMO, sold a total of 10,295 shares of common stock on September 2 and 3, 2026. According to the company’s disclosure, all of these shares were sold solely to satisfy tax withholding obligations arising from the vesting of restricted stock units, and no Rule 10b5-1 trading plan is reported.

Maze Therapeutics, Inc. (MAZE) reported that its General Counsel and Corporate Secretary, Courtney Phillips, exercised previously granted restricted stock units on September 1, 2026, receiving 11,000 shares of Common Stock through an RSU vesting event.

The 11,000 RSUs, each representing a contingent right to one share of Common Stock, vested in connection with an award that vests as to one-half of the total award on September 1, 2026 and September 1, 2027, subject to continued service. These RSUs do not expire; they either vest or are cancelled prior to the vesting date.

Maze Therapeutics, Inc. (MAZE) reported that Chief Strategy and Business Officer Atul Dandekar exercised restricted stock units into common stock on September 1, 2026. 12,500 restricted stock units converted into 12,500 shares of common stock at no cash exercise price, increasing his directly held common shares to 38,750. Each restricted stock unit represents a right to receive one share of common stock upon settlement and vests in two equal tranches on September 1, 2026 and September 1, 2027, subject to his continued service, with units either vesting or being cancelled and not expiring.

Maze Therapeutics, Inc. (MAZE) reported that Chief Executive Officer and director Jason V. Coloma had 50,000 restricted stock units settle into 50,000 shares of common stock on September 1, 2026. On the same date, entities for which he and his spouse serve as co‑trustees sold a total of 34,501 shares of common stock at weighted average prices around $26.30 per share under a Rule 10b5-1 trading plan. Following these transactions, the trusts reported holdings of 223,355 and 18,151 shares, and Coloma held 50,000 shares directly from the RSU settlement.

Maze Therapeutics, Inc. (MAZE) reported that President, R&D & CMO Harold Bernstein exercised stock options and restricted stock units and sold shares on September 1, 2026 pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025. He exercised options for 16,141 shares of common stock at an exercise price of $10.42 per share, received 16,141 shares of common stock, and sold those 16,141 shares at a weighted average price of $26.3622 per share in multiple trades between $26.11 and $26.64. He also converted 20,000 restricted stock units into 20,000 shares of common stock and continues to hold 20,000 restricted stock units that vest in two equal installments on September 1, 2026 and September 1, 2027, all reported as directly owned.

Maze Therapeutics, Inc. (MAZE) officer Atul Dandekar (CSBO) reported an option exercise and same-day sale. On 2026-08-28, he exercised 7,500 stock options for common stock at an exercise price of $10.42 per share, receiving 7,500 shares, then sold 7,500 common shares at a weighted average price of $27.5765 per share in transactions ranging from $27.31 to $28.01. The option, which became fully vested on March 17, 2025, now has 14,143 options reported as remaining and expires on 2031-04-11. All reported trades were effected under a Rule 10b5-1 trading plan adopted on September 29, 2025.

Maze Therapeutics director Sophie Kornowski received a grant of 36,000 stock options on August 13, 2026. The options have an exercise price of $27.665 per share and expire on August 12, 2036. They vest in 36 equal monthly installments beginning September 13, 2026, contingent on her continued service.

Maze Therapeutics director Paula A. Johnson received a grant of stock options for 36,000 shares of common stock. The options have an exercise price of $27.665 per share, expire on August 12, 2036, and vest in 36 equal monthly installments starting September 13, 2026, subject to continued service.

Maze Therapeutics, Inc. officer Harold Bernstein (President, R&D & CMO) exercised stock options and sold shares on August 13, 2026 under a Rule 10b5-1 trading plan adopted on September 29, 2025. He exercised options for 16,142 shares of common stock at an exercise price of $10.42 per share, reducing that option position and leaving 176,803 options outstanding from this award. The resulting 16,142 common shares were then sold at a weighted average price of $27.6063 per share, in multiple trades between $27.17 and $28.00. The options vest over four years, with 1/4 vested on October 3, 2023 and the remainder in equal monthly installments, conditioned on continued service.

Maze Therapeutics, Inc. Chief Executive Officer Jason V. Coloma reported indirect sales totaling 34,501 shares of common stock on August 3, 2026. Shares held by The Coloma 2021 Irrevocable Trust and the Coloma Family Trust, for which Coloma and his spouse are co‑trustees, were sold in four non‑derivative transactions at weighted average prices of $26.7145, $27.0940, $26.7140, and $27.0853 per share, executed pursuant to a Rule 10b5‑1 trading plan adopted on February 6, 2026.

Maze Therapeutics, Inc. officer Atul Dandekar reported exercising stock options for 7,500 shares of common stock at an exercise price of $10.42 per share and selling 7,500 shares of common stock in multiple transactions at weighted-average prices of $27.3064 and $27.89. These transactions were effected under a Rule 10b5-1 trading plan adopted on September 29, 2025. The fully vested option, which expires on April 11, 2031, left 21,643 options outstanding after the exercise.

Maze Therapeutics President, R&D & CMO Harold Bernstein executed an option exercise and share sale in a pre-planned transaction. He exercised stock options to acquire 14,609 shares of Common Stock at an exercise price of $10.42 per share and then sold 14,609 shares in open-market trades on the same date.

The sales occurred at weighted average prices of $29.8650 and $30.3369 per share under a Rule 10b5-1 trading plan adopted on September 29, 2025. Following these transactions, he reported holding 0 shares of Common Stock directly and 192,945 stock options (right to buy) outstanding.

Maze Therapeutics, Inc. director and Chief Executive Officer Jason V. Coloma reported indirect open-market sales of common stock totaling 34,501 shares on July 1, 2026, executed by family trusts.

The Coloma Family Trust sold 1,597 shares at a weighted average of $30.4359 per share and 30,311 shares at a weighted average of $29.9535 per share. The Coloma 2021 Irrevocable Trust sold 2,593 shares at a weighted average of $29.9754 per share. According to a footnote, these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 6, 2026, indicating they were scheduled in advance rather than timed discretionarily.

Maze Therapeutics CSBO Atul Dandekar executed an option exercise and share sale. On June 29, he exercised 7,500 stock options at $10.42 per share and sold 7,500 shares of common stock at $28.02 per share in an open-market transaction.

These trades were made under a pre-arranged Rule 10b5-1 trading plan. Following the sale, he holds 26,250 shares of common stock directly, including 1,442 shares acquired through the company’s Employee Stock Purchase Plan.

Maze Therapeutics, Inc. director and Chief Executive Officer Jason V. Coloma reported indirect open-market sales totaling 27,858 shares of common stock. The Coloma Family Trust and The Coloma 2021 Irrevocable Trust, for which Coloma and his spouse serve as co-trustees, executed these trades at weighted average prices near $26 per share. The filing notes the transactions were made pursuant to a Rule 10b5-1 trading plan adopted on February 6, 2026, indicating they were pre-arranged rather than discretionary market-timed sales.

Maze Therapeutics, Inc. director Daniel K. Spiegelman received a grant of stock options covering 18,000 shares of common stock. The options have an exercise price of $23.58 per share and expire on June 7, 2036. They vest and become fully exercisable on the earlier of the company’s 2027 annual stockholders meeting or June 8, 2027, subject to his continued service.

Maze Therapeutics, Inc. director Richard H. Scheller received a grant of stock options covering 18,000 shares of common stock. The options have an exercise price of $23.58 per share and expire on June 7, 2036.

The option award vests and becomes fully exercisable on the earlier of the company’s 2027 annual stockholders meeting or June 8, 2027, as long as Scheller continues to serve the company through that vesting date. This is a compensation-related grant rather than an open‑market transaction.

Maze Therapeutics director Jonathan E. Lim received a grant of 18,000 stock options for common stock. The options have an exercise price of $23.58 per share and bring his reported option holdings to 18,000.

The award vests and becomes fully exercisable on the earlier of the company’s 2027 annual stockholders meeting or June 8, 2027, if he continues serving the company through that date. This is a compensation-related grant rather than an open-market purchase or sale.

Maze Therapeutics director Herve Hoppenot received a grant of stock options to buy 18,000 shares of Common Stock at an exercise price of $23.58 per share. The options were granted on June 8, 2026 and will vest fully on the earlier of the company’s 2027 annual stockholders meeting or June 8, 2027, contingent on his continued service. The options expire on June 7, 2036 and are held directly, representing equity-based, non-cash compensation rather than an open-market transaction.

Maze Therapeutics director Charles J. Homcy received a grant of stock options covering 18,000 shares of common stock. The options have an exercise price of $23.58 per share and expire on June 7, 2036. They will vest and become fully exercisable on the earlier of the company’s 2027 annual stockholders meeting or June 8, 2027, subject to his continued service.

Maze Therapeutics director Nancy C. Andrews received a grant of 18,000 stock options to buy common stock. The options have an exercise price of $23.58 per share and expire on June 7, 2036. Following this grant, she holds 18,000 options.

The options will vest and become fully exercisable on the earlier of the company’s 2027 annual stockholders meeting or June 8, 2027, provided she continues serving the company through that vesting date.

Maze Therapeutics, Inc. director and CEO Jason V. Coloma reported indirect open-market sales of company common stock by two family trusts associated with him. On June 1, 2026, the Coloma Family Trust sold 6,090 shares at a weighted average price of $26.1965 per share, leaving it with 344,897 shares. The Coloma 2021 Irrevocable Trust sold 553 shares at a weighted average price of $26.2412, leaving it with 27,970 shares. A footnote states these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 6, 2026, indicating they were scheduled in advance rather than timed discretionarily.

Maze Therapeutics, Inc. President, R&D & CMO Harold Bernstein exercised stock options for 14,853 shares of common stock at an exercise price of $10.42 per share, then sold all 14,853 shares in open-market transactions at weighted average prices of $25.57 and $26.36 per share. These trades were executed under a pre-arranged Rule 10b5-1 trading plan, and he reported no directly held common shares afterward while retaining 207,554 stock options following the option exercise.

Maze Therapeutics, Inc. chief business officer Atul Dandekar reported option exercises and related share sales. On May 29, 2026, he exercised stock options to acquire 7,500 shares of common stock at $10.42 per share and then sold 7,500 shares in open-market transactions at a weighted average price of $26.3405 per share. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 29, 2025. After these transactions, he directly owned 24,808 shares of Maze Therapeutics common stock.

Maze Therapeutics, Inc. director and CEO Jason V. Coloma reported indirect open-market sales of 32,564 shares of common stock, executed on May 22, 2026 and May 26, 2026.

The sales were made by the Coloma Family Trust and The Coloma 2021 Irrevocable Trust, where Coloma and his spouse serve as co-trustees. Reported prices were weighted averages around $26.00 per share, across multiple trades within narrow price ranges.

Following the latest transactions, the Coloma Family Trust held 350,987 shares and The Coloma 2021 Irrevocable Trust held 28,523 shares of Maze Therapeutics common stock. One of the transactions was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 6, 2026, indicating a scheduled selling program rather than purely discretionary timing.

Maze Therapeutics, Inc. director and Chief Executive Officer Jason V. Coloma reported open-market sales of common stock executed by family trusts associated with him. On May 15, 2026, The Coloma 2021 Irrevocable Trust sold 116 shares and the Coloma Family Trust sold 1,822 shares, each at $26.00 per share, for a total of 1,938 shares sold.

After these sales, the Coloma Family Trust held 381,073 shares of Maze Therapeutics common stock and The Coloma 2021 Irrevocable Trust held 31,001 shares. The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted by Coloma.

Maze Therapeutics, Inc. President, R&D & CMO Harold Bernstein reported an exercise-and-sell transaction in Common Stock. On May 14, 2026, he exercised stock options to acquire 15,000 shares at $10.42 per share, then sold the same 15,000 shares in open-market transactions at a weighted average price of $26.2236 per share, with individual sale prices ranging from $25.77 to $26.44. These trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on September 29, 2025. After the sale, he reported holding no Common Stock directly, while retaining 222,407 stock options with a $10.42 exercise price expiring on October 26, 2032.

Maze Therapeutics, Inc. Chief Business and Strategy Officer Atul Dandekar exercised stock options to acquire a total of 14,305 shares of Common Stock on May 4, 2026. The options were exercised at an exercise price of $10.42 per share.

Following these transactions, Dandekar directly holds 24,808 shares of Common Stock. The exercised options relate to awards that vest monthly over 48 months, with one award noted as having become fully vested on February 1, 2026, subject to continued service conditions described in the award agreements.

Maze Therapeutics, Inc. director Charles J. Homcy reported a bona fide gift transfer of 7,422 shares of common stock on May 4, 2026. The gift was made for no consideration and is described as exempt under Rule 16b-5. After the transaction, Homcy directly holds 31,113 shares of Maze Therapeutics common stock, a total that includes shares previously held by the Charles J. Homcy Revocable Trust UA 11/4/1998.

Maze Therapeutics, Inc. chief business officer Atul Dandekar exercised stock options for 7,500 shares of common stock at $10.42 per share and on the same day sold 7,500 shares in an open-market transaction at a weighted average price of $25.3732 per share. Following these transactions, he directly holds 10,503 shares of Maze common stock. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan, indicating the timing was set in advance rather than decided opportunistically.

Maze Therapeutics executive Harold Bernstein, President, R&D & CMO, exercised stock options to acquire 15,000 shares of common stock at an exercise price of $10.42 per share on April 1, 2026. He then sold the same 15,000 shares in open-market transactions at weighted average prices of $29.24, $30.06, and $31.07 per share pursuant to a pre-arranged Rule 10b5-1 trading plan. Following these transactions, his direct common stock holdings from this block were reduced to zero, while he continued to hold 237,407 stock options after the exercise.

Maze Therapeutics SVP of Finance Amy Bachrodt exercised stock options and sold shares in a planned transaction. She exercised options to acquire 2,500 shares of Common Stock at $10.42 per share, then sold a total of 2,500 shares in open-market trades at weighted average prices of $29.3227 and $30.3367 per share. These sales were executed under a Rule 10b5-1 trading plan adopted on September 29, 2025. Following the transactions, she directly owns 12,965 shares of Common Stock.

Maze Therapeutics CSBO Atul Dandekar reported an exercise-and-sell transaction in company stock. On March 30, 2026, he exercised 7,500 stock options at $10.42 per share, acquiring an equal number of Maze Therapeutics common shares.

That same day, he sold a total of 7,500 common shares in two open-market transactions at weighted average prices of $29.2556 and $30.0173 per share, executed under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, he directly owns 10,503 common shares and holds 51,643 stock options that remain outstanding.

Maze Therapeutics director Neil Kumar received a grant of stock options to buy 33,417 shares of Common Stock. The options carry an exercise price of $30.38 per share and expire on March 26, 2036. They vest in 36 equal monthly installments starting April 27, 2026, contingent on his continued service.

Maze Therapeutics, Inc. President, R&D & CMO Harold Bernstein exercised stock options to acquire 15,000 shares of common stock at $10.42 per share. On the same day, he sold those 15,000 shares in open-market transactions at weighted average prices between $47.77 and $50.52 per share. The sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 29, 2025, indicating a scheduled liquidity event rather than a discretionary trade.

Maze Therapeutics, Inc. President, R&D & CMO Harold Bernstein exercised stock options for 30,000 shares of common stock at an exercise price of $10.42 per share and then sold 30,000 shares in open-market transactions on the same date.

The sales were executed in two tranches at weighted-average prices of $50.4454 and $51.0150 per share under a pre-arranged Rule 10b5-1 trading plan adopted on September 29, 2025. Following these transactions, he reported direct ownership of 0 common shares and 267,407 options remaining from the underlying award, which continues to vest monthly through October 2027.

Tahir Misbah reported acquisition or exercise transactions in this Form 4 filing.

Maze Therapeutics, Inc. reported that Chief Financial Officer Tahir Misbah received equity awards consisting of a stock option for 40,000 shares and 20,000 restricted stock units, both granted at a price of $0.00 per share.

The option award vests monthly in 1/48 increments, with the first portion vesting on April 1, 2026, as long as he continues serving the company. The restricted stock units vest in four equal annual installments, starting on March 1, 2027, with each unit representing the right to receive one share of common stock when it settles. These RSUs either vest or are cancelled before vesting.

Courtney Phillips reported acquisition or exercise transactions in this Form 4 filing.

Maze Therapeutics, Inc. reported that its General Counsel and Corporate Secretary, Courtney Phillips, received equity awards consisting of stock options and restricted stock units. The grant covers 32,000 options that vest monthly over four years starting on April 1, 2026, and 16,000 RSUs that vest annually in four equal installments beginning on March 1, 2027, in each case conditioned on continued service.

Maze Therapeutics, Inc. chief business and strategy officer Atul Dandekar reported a mix of equity awards, option exercise, and share sales. He received a grant of 38,000 stock options and 19,000 restricted stock units, each at an exercise or acquisition price of $0.00 per share.

On February 27, 2026, he exercised 7,500 stock options at $10.42 per share to acquire 7,500 shares of common stock, then sold 3,739 shares at a weighted average price of $45.134 and 3,761 shares at $45.7238. The sales were made under a Rule 10b5-1 trading plan adopted on September 29, 2025.

Following these transactions, he directly held 10,503 shares of common stock, 59,143 stock options and 19,000 restricted stock units. The new option award vests in 1/48 increments monthly starting April 1, 2026, while the RSUs vest in four annual tranches beginning March 1, 2027.

Maze Therapeutics, Inc. reported that Chief Executive Officer Jason V. Coloma received new equity awards. He was granted a stock option for 150,000 shares with a zero exercise price shown in the filing, vesting in 1/48 monthly tranches starting on April 1, 2026, as long as he remains in service.

Coloma was also granted 75,000 restricted stock units, each representing the right to receive one share of common stock upon settlement. These RSUs vest in four equal annual installments, with the first 1/4 vesting on March 1, 2027 and the remaining tranches vesting on each anniversary, subject to continued service. The RSUs do not expire; they either vest or are cancelled before vesting.

Maze Therapeutics SVP, Finance Amy Bachrodt reported multiple equity transactions on March 2, 2026. She exercised a stock option for 5,000 shares of common stock at $10.42 per share and received a new stock option grant for 32,000 shares plus 16,000 restricted stock units, all held directly.

On the same date, she sold 1,300 shares of common stock at a weighted average price of $44.4414 and 3,700 shares at a weighted average price of $45.4694, in open‑market transactions under a Rule 10b5‑1 trading plan adopted on September 29, 2025. The footnotes note price ranges for these weighted averages and describe monthly vesting for the options and annual vesting tranches for the RSUs, subject to continued service.

Maze Therapeutics insider awarded stock options and RSUs. On March 2, 2026, a reporting person who is a 10% owner and serves as President, R&D & CMO received 48,000 stock options with an exercise price of $45.61 per share, expiring on March 1, 2036. These options vest monthly over four years, with the first 1/48 tranche on April 1, 2026, contingent on continued service.

The insider was also granted 24,000 restricted stock units, each representing one share of common stock. This RSU award vests in four equal annual installments, starting on March 1, 2027, also subject to continued service. Unvested RSUs either vest on schedule or are cancelled before vesting.

Maze Therapeutics President, R&D & CMO Harold Bernstein reported an automatic stock transaction under a Rule 10b5-1 trading plan. On February 2, 2026, he exercised a stock option for 15,000 shares of common stock at an exercise price of $10.42 per share.

On the same date, he sold a total of 15,000 common shares in several market transactions at weighted average prices of $44.205, $45.8891, $46.3732 and $47.23 per share, with actual sale prices ranging from $44.15 to $47.17 per share. After these sales, he reported 0 shares of common stock directly owned and 297,407 stock options remaining, linked to an award that began vesting on October 3, 2023.

Maze Therapeutics SVP Finance Amy Bachrodt reported option exercises and share sales. On February 2, 2026, she exercised stock options for 4,844 and 156 shares of common stock at an exercise price of $10.42 per share.

That same day she sold 200 shares at $44.15, 4,064 shares at a weighted average price of $46.0305, and 736 shares at a weighted average price of $46.6323. The sales were effected under a Rule 10b5-1 trading plan. After these transactions, she directly owned 12,965 common shares, along with vested and vesting stock options.

Maze Therapeutics, Inc. executive Atul Dandekar reported an option exercise and planned share sales. On January 29, 2026, he exercised a stock option for 7,500 shares of common stock at $10.42 per share, from a fully vested award. The same day, he sold 7,500 common shares in three trades: 1,200 shares at $43.1844, 3,500 shares at $44.0419, and 2,800 shares at $45.008, all under a pre-established Rule 10b5-1 trading plan. After these transactions, he reported owning 10,503 shares of common stock and 66,643 stock options, all held directly.

Maze Therapeutics SVP of Finance Amy Bachrodt reported option exercises and a stock sale. On January 22, 2026, she exercised stock options to acquire 2,497 and 2,503 shares of common stock at an exercise price of $10.42 per share. On the same date, she sold 5,000 shares of common stock at a weighted average price of $45.5224 per share under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, she directly held 12,965 shares of Maze Therapeutics common stock and retained stock options covering 486 and 7,869 shares, subject to monthly vesting schedules.